Fidexaban
Alternative Names: BX 807834; CI 1031; ZK 807834Latest Information Update: 30 Aug 2004
Price :
$50 *
At a glance
- Originator Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma; Pfizer
- Class Anticoagulants; Antithrombotics; Small molecules
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis; Unstable angina pectoris
Most Recent Events
- 15 Jun 2004 Discontinued - Clinical-Phase-Unknown for Thrombosis in USA (unspecified route)
- 15 Jun 2004 Discontinued - Phase-I for Unstable angina pectoris in Europe (PO)
- 15 Jun 2004 Discontinued - Phase-I for Unstable angina pectoris in USA (PO)